Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.